Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis

Neurotherapeutics

Volumn 10, Issue 1, 2013, Pages 77-88

  Stankiewicz, James M ^a   Kolb, Hadar ^b   Karni, Arnon ^b   Weiner, Howard L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Azathioprine; Cyclophosphamide; Methotrexate; Mitoxantrone; Mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ALOPECIA; BEHAVIOR CHANGE; BLADDER CANCER; BRAIN DISEASE; CASE REPORT; DETERIORATION; DIARRHEA; DIFFUSION WEIGHTED IMAGING; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPHAGIA; GILBERT DISEASE; HAIR DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; LEUKOCYTE COUNT; MALE; MOUTH ULCER; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY POLYCYSTIC DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; STEREOTACTIC BIOPSY; VOMITING; WHITE MATTER LESION;

EID: 84873118734     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0172-3     Document Type: Review

References (74)

1. Calne DB, Leibowitz S. Suppression of experimental allergic encephalomyelitis by cytotoxic drugs. Nature 1963; 197: 1309-1310.
2. Aimard G, Girard PF, Raveau J. Multiple sclerosis and the autoimmunization process. Treatment by antimitotics. Lyon Med 1966; 215: 345-352.
3. ten Berge RJ, van Walbeek HK, Schellekens PT. Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis. Clin Exp Immunol 1982; 50: 495-502.
4. Brinkman CJ, Nillesen WM, Hommes OR. T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: effect of cyclophosphamide. Clin Immunol Immunopathol 1983; 29: 341-348.
5. Hommes OR, Aerts F, Bahr U, Schulten HR. Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression. J Neurol Sci 1983; 58: 297-303.
6. Hafler DA, Orav J, Gertz R, Stazzone L, Weiner HL. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol 1991; 32: 149-158.
7. Mickey MR, Ellison GW, Fahey JL, Moody DJ, Myers LW. Correlation of clinical and immunologic states in multiple sclerosis. Arch Neurol 1987; 44: 371-375.
8. Takashima H, Smith DR, Fukaura H, et al. Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. Clin Immunol Immunopathol 1998; 88: 28-34.
9. Comabella M, Balashov K, Issazadeh S, et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998; 102: 671-678.
10. Karni A, Balashov K, Hancock WW, et al. Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol 2004; 146: 189-198.
11. Hommers OR, Lamers KJ, Reekers P. Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis. J Neurol 1980; 223: 177-190.
12. Gonsette RE, Demonty L, Delmotte P. Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years. J Neurol 1977; 214: 173-181.
13. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173-180.
14. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-446.
15. Likosky WH, Fireman B, Elmore R, et al. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 1991; 54: 1055-1060.
16. Manova MG, Kostadinova, II, Rangelov AA. Clinico-laboratory study of methylprednisolone and cyclophosphamide treatment in patients with multiple sclerosis relapse. Folia Med (Plovdiv) 2000; 42: 20-25.
17. D'Andrea F, D'Aurizio C, Marini C, Prencipe M. Cyclophosphamide in relapsing remitting multiple sclerosis. Ital J Neurol Sci 1990; 11: 271-274.
18. Killian JM, Bressler RB, Armstrong RM, Huston DP. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol 1988; 45: 27-30.
19. Khan OA, Zvartau-Hind M, Caon C, et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 2001; 7: 185-188.
20. Smith DR, Weinstock-Guttman B, Cohen JA, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler 2005; 11: 573-582.
21. Gobbini MI, Smith ME, Richert ND, Frank JA, McFarland HF. Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmunol 1999; 99: 142-149.
22. Patti F, Reggio E, Palermo F, et al. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol 2004; 251: 1502-1506.
23. Patti F, Cataldi ML, Nicoletti F, et al. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 71: 404-407.
24. Reggio E, Nicoletti A, Fiorilla T, et al. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-twenty-four months follow-up. J Neurol 2005; 252: 1255-1261.
25. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910-918.
26. Zephir H, de Seze J, Duhamel A, et al. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 2004; 218: 73-77.
27. Makhani N, Gorman MP, Branson HM, et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009; 72: 2076-2082.
28. Yeh EA, Weinstock-Guttman B. Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide. Neurology 2009; 72: 2064-2065.
29. Hohol MJ, Olek MJ, Orav EJ, et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler 1999; 5: 403-409.
30. Zipoli V, Portaccio E, Hakiki B, et al. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci 2008; 266: 25-30.
31. Myers LW, Fahey JL, Moody DJ, et al. Cyclophosphamide 'pulses' in chronic progressive multiple sclerosis. A preliminary clinical trial. Arch Neurol 1987; 44: 828-832.
32. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL. Immunosuppression with high-dose i. v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988; 38: 9-14.
33. Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008; 65: 1044-1051.
34. Harrison DM, Gladstone DE, Hammond E, et al. Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Mult Scler 2012; 18: 202-209.
35. Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557.
36. Portaccio E, Zipoli V, Siracusa G, et al. Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. Mult Scler 2003; 9: 446-450.
37. Boumpas DT, Austin HA, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-369.
38. Slater CA, Liang MH, McCune JW, Christman GM, Laufer MR. Preserving ovarian function in patients receiving cyclophosphamide. Lupus 1999; 8: 3-10.
39. Patti F, Lo Fermo S. Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis 2011; 2011: 961702.
40. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau FA. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997; 6: 254-257.
41. Morgenstern LB, Pardo CA. Progressive multifocal leukoencephalopathy complicating treatment for Wegener's granulomatosis. J Rheumatol 1995; 22: 1593-1595.
42. Yokoyama H, Watanabe T, Maruyama D, et al. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol 2008; 88: 443-447.
43. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
44. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995; 38: 1120-1127.
45. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 477-484.
46. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991; 20: 194-208.
47. Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. BMJ 1979; 2: 1461-1466.
48. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
49. Ahrens N, Salama A, Haas J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001; 248: 713-714.
50. Frohman EM, Brannon K, Racke MK, Hawker K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004; 27: 80-83.
51. Vermersch P, Waucquier N, Michelin E, et al. Combination of IFN beta-1a (Avonex) and mycophenolate mofetil (Cellcept) in multiple sclerosis. Eur J Neurol 2007; 14: 85-89.
52. Frohman EM, Cutter G, Remington G, et al. A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2010; 3: 15-28.
53. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66: 1128-1133.
54. Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010; 33: 969-983.
55. Neuhaus O, Kieseier BC, Hartung HP. Immunosuppressive agents in multiple sclerosis. Neurotherapeutics 2007; 4: 654-660.
56. Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 2007: CD003982.
57. Havrdova E, Zivadinov R, Krasensky J, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 2009; 15: 965-976.
58. Kalincik T, Horakova D, Dolezal O, et al. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clin Neurol Neurosurg 2012; 114: 940-6.
59. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. J Neurol 2007; 254: 1723-1728.
60. Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 1988; 2: 179-183.
61. Lhermitte F, Marteau R, Roullet E. Not so benign long-term immunosuppression in multiple sclerosis? Lancet 1984; 1: 276-277.
62. Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996; 46: 1607-1612.
63. Amato MP, Pracucci G, Ponziani G, et al. Long-term safety of azathioprine therapy in multiple sclerosis. Neurology 1993; 43: 831-833.
64. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-118.
65. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025.
66. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 1463-1670.
67. Neumann JW, Ziegler DK. Therapeutic trial of immunosuppressive agents in multiple sclerosis. Neurology 1972; 22: 1268-1271.
68. Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 1993; 56: 1217-1218.
69. Ashtari F, Savoj MR. Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon beta-1alpha: A randomized controlled trial. J Res Med Sci 2011; 16: 457-462.
70. Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002; 58: 314-317.
71. Cohen JA, Imrey PB, Calabresi PA, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009; 72: 535-541.
72. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7. 5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30-40.
73. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, van Dyke C. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 1996; 47: 1153-1157.
74. Sadiq SA, Simon EV, Puccio LM. Intrathecal methotrexate treatment in multiple sclerosis. J Neurol 2010; 257: 1806-1811.